Recardio

Regenerative Cardiac Medicine of Tomorrow

  • Company
    • Profile
    • Management Board
    • Boards
    • Awards
  • Pipeline
    • Background
    • Rationale
    • Therapy
  • Clinical Studies
    • Phase 1
    • Phase 2B AMI
    • Phase 2B CHF
  • News
  • Apps
    • App Privacy Policy

Mar 21 2019

Recardio presented at the Cell & Gene Therapy Conference in New York

San Francisco, March 21, 2019 – Recardio announced today that it presented at the Cell & Gene Therapy Conference in New York.

Read More

Written by Recardio · Categorized: Uncategorized

Jan 07 2019

Recardio at J.P. Morgan Conference 2019

San Francisco, January 07, 2019 – Recardio Inc., a clinical-stage life science company focusing on regenerative therapies for cardiovascular diseases, today announced that it is participating in the 37thAnnual J.P. Morgan Healthcare Conference on January 7thin San Francisco.

Read More

Written by Recardio · Categorized: Uncategorized

Dec 13 2018

Recardio’s Phase 2 Regenerative Post-Myocardial Infarction Trial of Dutogliptin Enrolled First Patients and Recruiting in Multiple Centers

San Francisco, December 13, 2018 – Recardio Inc., a life science company developing regenerative therapies for cardiovascular diseases,announced that its Phase 2 study of dutogliptin in combination with filgrastim in early recovery post-myocardial infarction has now enrolled the first patients and is now recruiting in multiple European centers. The remaining sites in Europe and in the US will join in the coming months.

Read More

Written by Recardio · Categorized: Uncategorized

Oct 17 2018

Recardio at BIO Investor Forum 2018 in San Francisco

San Francisco, October 17, 2018 – Recardio Inc. presented today its clinical regenerative therapy program for cardiovascular diseases at the international BIO Investor Forum 2018 in San Francisco.

Read More

Written by Recardio · Categorized: Uncategorized

Aug 25 2018

Recardio presents at the 2018 Annual Meeting of the European Society of Cardiology in Munich

San Francisco, August 25, 2018 – Recardio Inc., a life science company developing regenerative therapies for cardiovascular diseases, announced that its Chief Scientific Officer, Darrell Nix, Ph.D., presented today the findings of a Phase 1 study of its lead drug candidate dutogliptin for the treatment of patients in early recovery post-myocardial infarction.  

Read More

Written by Recardio · Categorized: Uncategorized

  • 1
  • 2
  • 3
  • Next Page »
  • Contact us
  • Imprint
  • Data Privacy

© Recardio inc. 2019 · All Rights Reserved

Copyright © 2019 · Genesis Framework · WordPress · Log in